Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.81 |
| ▸ | CA2 | P00918 | 1/20 | 0.81 |
| ▸ | CA9 | Q16790 | 1/20 | 0.81 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.79 |
| ▸ | TSHR | P16473 | 1/20 | 0.73 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 11/20 | 0.71 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | HTT | P42858 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.53 |
| ▸ | GBA1 | P04062 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18553819 | 0.90 | CA12 (1.00) | CA12CA2CA9ALOX15TSHR | |
| SCHEMBL12629636 | 0.89 | ALDH1A1 (0.71) | CA12CA2CA9ALOX15TSHR | |
| SCHEMBL1348425 | 0.86 | TSHR (0.73) | CA12CA2CA9ALOX15TSHR | |
| SCHEMBL4581466 | 0.86 | ALDH1A1 (0.71) | CA12CA2CA9ALOX15TSHR | |
| SCHEMBL6355304 | 0.86 | ALDH1A1 (0.71) | CA12CA2CA9ALOX15TSHR | |
| SCHEMBL5567042 | 0.85 | ALDH1A1 (0.75) | CA12CA2CA9ALOX15ALDH1A1 | |
| SCHEMBL19152453 | 0.84 | TSHR (0.71) | CA12CA2CA9ALOX15TSHR | |
| SCHEMBL7028080 | 0.84 | TSHR (0.71) | CA12CA2CA9ALOX15TSHR | |
| SCHEMBL3327488 | 0.84 | TSHR (0.71) | CA12CA2CA9ALOX15TSHR | |
| SCHEMBL19563408 | 0.84 | SIGMAR1 (0.71) | CA12CA2CA9ALOX15TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119490438-A | Water-soluble quaternary ammonium salt antibacterial agent and preparation method thereof | 苏州华道生物药业股份有限公司 | 2025-02-21 | — | — | CN | disclosed |
| US-20230321016-A1 | COMBINATION THERAPY FOR TREATING CANCER | GONGWIN BIOPHARM CO., LTD (TW) | 2023-10-12 | — | — | US | disclosed |
| US-20230321016-A1 | COMBINATION THERAPY FOR TREATING CANCER | GONGWIN BIOPHARM CO., LTD (TW) | 2023-10-12 | — | — | US | disclosed |
| US-11752118-B2 | Method for treating melanoma | GONGWIN BIOPHARM CO., LTD (TW) | 2023-09-12 | — | — | US | disclosed |
| US-11752160-B2 | Method for reducing fat by administering benzenesulfonamide compositions | GONGWIN BIOPHARM CO., LTD (TW) | 2023-09-12 | — | — | US | disclosed |
| US-11752118-B2 | Method for treating melanoma | GONGWIN BIOPHARM CO., LTD (TW) | 2023-09-12 | — | — | US | disclosed |
| US-11752160-B2 | Method for reducing fat by administering benzenesulfonamide compositions | GONGWIN BIOPHARM CO., LTD (TW) | 2023-09-12 | — | — | US | disclosed |
| US-20230062022-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | NUVATION BIO INC (US) | 2023-03-02 | — | — | US | disclosed |
| WO-2022236256-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | NUVATION BIO INC. (US) | 2022-11-10 | — | — | WO | disclosed |
| WO-2022236253-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | NUVATION BIO INC. (US) | 2022-11-10 | — | — | WO | disclosed |
| US-20080113985-A1 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED | 2008-05-15 | — | — | US | disclosed |
| US-20080019915-A1 | including cystic fibrosis transmembrane conductance regulator (\"CFTR\"); N[6-(2-hydroxymethylphenyl-1yl)-5-methylpyrimidine][(4-methoxophenyl-1-yl)cyclopopyl]-amide; genetic disorders; respiratory system disorders, cystic fibrosis, hereditary emphysema and hemochromatosis, coagulation-fibrinolysis | VERTEX PHARMACEUTICALS INCORPORATED | 2008-01-24 | — | — | US | disclosed |
| US-20070225296-A1 | Arylalkylamine Compound and Process for Preparing the Same | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-09-27 | — | — | US | disclosed |
| US-20070225296-A1 | Arylalkylamine Compound and Process for Preparing the Same | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-09-27 | — | — | US | disclosed |
| US-20050064468-A1 | concentration, removing or separation of nucleotide bases or nucleotide sequences containing bases from solid supports | IBC ADVANCED TECHNOLOGIES, INC. | 2005-03-24 | — | — | US | disclosed |
| EP-1453602-A4 | COMPOSITIONS AND METHODS FOR SEPARATING HETEROCYCLIC AROMATIC AMINE BASES, NUCLEOSIDES, NUCLEOTIDES, AND NUCLEOTIDE SEQUENCES | IBC ADVANCED TECH INC (US) | 2005-01-12 | — | — | EP | disclosed |
| EP-1453602-A2 | COMPOSITIONS AND METHODS FOR SEPARATING HETEROCYCLIC AROMATIC AMINE BASES, NUCLEOSIDES, NUCLEOTIDES, AND NUCLEOTIDE SEQUENCES | IBC ADVANCED TECHNOLOGIES, INC. (US) | 2004-09-08 | — | — | EP | disclosed |
| US-6774082-B2 | COMPOSITION FOR USE IN THE SEPARATION OF PREFERENTIAL BIOPOLYMERS FROM SAMPLE | IBC ADVANCED TECHNOLOGIES, INC. | 2004-08-10 | — | — | US | disclosed |
| US-20030050458-A1 | Compositions and methods for separating heterocyclic aromatic amine bases, nucleosides, nucleotides, and nucleotide sequences | IBC ADVANCED TECHNOLOGIES, INC. | 2003-03-13 | — | — | US | disclosed |
| WO-2002092766-A2 | COMPOSITIONS AND METHODS FOR SEPARATING HETEROCYCLIC AROMATIC AMINE BASES, NUCLEOSIDES, NUCLEOTIDES, AND NUCLEOTIDE SEQUENCES | IBC ADVANCED TECHNOLOGIES, INC. (US) | 2002-11-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11752160-B2 | Method for reducing fat by administering benzenesulfonamide compositions | LIPE, FABP4, LIPA | CA12 4026/4885CA2 4175/4885CA9 1505/4885 |
| US-20080019915-A1 | including cystic fibrosis transmembrane conductance regulator (\"CFTR\"); N[6-(2-hydroxymethylphenyl-1yl)-5-methylpyrimidine][(4-methoxophenyl-1-yl)cyclopopyl]-amide; genetic disorders; respiratory system disorders, cystic fibrosis, hereditary emphysema and hemochromatosis, coagulation-fibrinolysis | CFTR, ABCC8, ABCB1 | CA12 4789/4885CA2 3603/4885CA9 4302/4885 |
| US-20070225296-A1 | Arylalkylamine Compound and Process for Preparing the Same | CASR, CNR1, CNR2 | CA12 1721/4885CA2 90/4885CA9 645/4885 |
| US-20230062022-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | CDK4, CDK6, CDK8 | CA12 3909/4885CA2 4392/4885CA9 3051/4885 |
| US-20230321016-A1 | COMBINATION THERAPY FOR TREATING CANCER | TP53, MCL1, TOP2B | CA12 239/4885CA2 989/4885CA9 76/4885 |
| US-20030050458-A1 | Compositions and methods for separating heterocyclic aromatic amine bases, nucleosides, nucleotides, and nucleotide sequences | NUDT1, ATIC, PNP | CA12 2357/4885CA2 2291/4885CA9 2526/4885 |
| US-20080113985-A1 | Modulators of ATP-binding cassette transporters | CFTR, ABCB1, ABCC2 | CA12 4730/4885CA2 2789/4885CA9 4024/4885 |
| US-11752118-B2 | Method for treating melanoma | TYR, MITF, BRAF | CA12 376/4885CA2 1053/4885CA9 132/4885 |
| US-20050064468-A1 | concentration, removing or separation of nucleotide bases or nucleotide sequences containing bases from solid supports | NUDT1, PCNA, NSUN2 | CA12 2216/4885CA2 1909/4885CA9 2096/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.